ArticleFunctional & integrative genomics2026
A hypoxia-responsive migrasome-related lncRNA signature predicts prognosis and suggests the MSC-AS1/ITGA5 axis as a potential therapeutic target in head and neck squamous cell carcinoma.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy associated with dismal prognosis. Migrasomes, a unique class of migration-dependent extracellular vesicles, have emerged as pivotal mediators of intercellular crosstalk within the tumor microenvironment. However, the clinical implications and regulatory mechanisms of migrasome-related long non-coding RNAs (MRLs) in HNSCC remain largely unexplored. Herein, we retrieved transcriptomic and clinical data of HNSCC from The Cancer Genome Atlas (TCGA) and established a prognostic signature using LASSO-Cox regression analysis, which was further internally validated in a randomly split subset of the TCGA cohort as internal validation. We systematically characterized the immune microenvironment and drug sensitivity profiles stratified by this signature, and identified the cellular distribution of core MRLs via single-cell RNA sequencing. Functional experiments were performed in clinical specimens and HNSCC cell lines using RT-qPCR, Western blot, CCK-8, and wound-healing assays. Consequently, a 10-MRL prognostic model was constructed to effectively stratify patients into high- and low-risk groups with significantly divergent overall survival, representing an independent prognostic factor in the context of the available clinical covariates from TCGA. High-risk patients exhibited an immunosuppressive tumor microenvironment and activation of oncogenic pathways (NF-κB, JAK-STAT). Mechanistically, MSC-AS1 was upregulated in HNSCC and facilitated cell proliferation and migration. Hypoxia upregulated the MSC-AS1/ITGA5 axis and increased VEGFA/PD-L1 expression, along with changes in the migrasome-related protein TSPAN4, suggesting a potential association with migrasome-related molecular features, which requires direct experimental validation. Collectively, our findings establish a novel MRL-based signature for prognostic prediction in HNSCC and highlight the hypoxia-responsive MSC-AS1/ITGA5 axis as a promising target for combinatorial therapeutic strategies.
Indexed as
Identifiers
42380675What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.